Breast cancer trial lets early response guide treatment switch
NCT ID NCT07616453
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II study tests a personalized approach for women with a common type of early breast cancer (HR+/HER2-). All 45 participants start with a combination of culmerciclib and hormone therapy. If the tumor responds well, they continue; if not, they switch to a different treatment before surgery. The goal is to improve outcomes and avoid ineffective therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Culmerciclib (a CDK2/4/6 inhibitor) plus aromatase inhibitors (letrozole or anastrozole)
- What this could lead to
- If successful, this could show that adapting treatment based on early response improves outcomes and avoids ineffective therapy for people with a common type of breast cancer.
- What could go wrong
- This is a small, early-phase study (45 people) without a control group, so results may not be definitive. The drug combination may cause side effects or fail to improve response rates.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR+/HER2- EARLY BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
2nd Affiliated Hospital, School of Medicine, Zhejiang University
RECRUITINGHangzhou, Zhejiang, 310009, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a 14-Hour fast ease breast cancer treatment side effects?
- Coaching may boost adherence to breast cancer therapy
- New breast cancer trial aims to skip chemo for some patients
- Could a pill replace chemo for some breast cancer patients?
- Breast cancer drug adherence under the microscope: will patients stick with treatment?
- Coaching may boost cancer pill adherence in new study